This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

SHLOMO MELMED, MD; GLENN D. BRAUNSTEIN, MD

Arch Intern Med. 1989;149(2):258-259.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Bromocriptine mesylate, a long-acting dopamine agonist, is a semisynthetic ergot-derived alkaloid that has been used clinically since 1969.¹ This drug has been effective in the management of patients with hyperprolactinemia with or without a demonstrable prolactin-secreting adenoma, growth hormone-secreting pituitary adenomas, postpartum lactation, and Parkinson's disease.² The drug also has been safely used in the management of pregnant women harboring prolactin-secreting pituitary tumors.³ In addition, the drug has been tried in some patients with luteal-phase insufficiency, idiopathic edema, premenstrual tension syndrome, and hepatic encephalopathy, although the data supporting the use of the drug in these latter conditions either are incomplete or require substantiation.¹

During the 20 years of clinical experience, bromocriptine has been found to be remarkably free of major side effects.⁴ Patients commonly develop nausea, occasionally with abdominal cramps and vomiting, and postural hypotension at the time therapy is initiated. These side effects can . . . [Full Text PDF of this Article]

Author Affiliations
Cedars-Sinai Medical Center 8700 Beverly Blvd Los Angeles, CA 90048

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?